Brief Communication

The FDA MyStudies app: a reusable platform for distributed clinical trials and real-world evidence studies

Zachary Wyner1, Sascha Dublin2, Christina Chambers3, Shyam Deval4, Chayim Herzig-Marx5, Shanthala Rao4, Adam Rauch6, Juliane Reynolds5, Jeffrey S. Brown5 and David Martin7

1Dana-Farber Cancer Institute, Boston, Massachusetts, USA, 2Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA, 3Department of Pediatrics, University of California, San Diego, La Jolla, California, USA, 4Boston Technology Corporation, Boston, Massachusetts, USA, 5Division of Therapeutics Research and Infectious Disease Epidemiology, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA, 6LabKey, Seattle, Washington, USA and 7Moderna, Inc, Cambridge, Massachusetts, USA

Corresponding Author: Jeffrey Brown, Division of Therapeutics Research and Infectious Disease Epidemiology, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Landmark Center 401 Park Drive, Suite 401 East, Boston, MA 02215, USA (jeff_brown@harvardpilgrim.org)

This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.

Received 23 March 2020; Revised 3 September 2020; Editorial Decision 11 October 2020; Accepted 31 October 2020

ABSTRACT

We developed a mobile application and secure patient data storage platform, FDA MyStudies, to address privacy, engagement, and extensibility challenges in mobile clinical research. The system extends the capabilities of the mobile frameworks Apple ResearchKit and ResearchStack through an intuitive front-end application and secure storage environment that can support health research studies. The platform supports single or multisite studies via role-based access and can be implemented within highly secure data environments. As a proof-of-concept, pregnant women participated in a descriptive study via the app in which data not routinely captured in electronic health records (EHR) were collected and linked with existing patient data to provide a more wholistic view of the patient and illustrate how patient data combined with EHR data could be used to support public health research.

Key words: mobile app, digital health, patient-generated data, mobile devices, open source, web-based configuration, real-world evidence, clinical trials, research studies, ResearchKit, ResearchStack

BACKGROUND AND SIGNIFICANCE

Despite the promise of “Big Data,” most comparative effectiveness and drug safety research in the United States relies on electronic health records (EHR) and health care claims data. However, these data sources do not reliably capture information critical to the conduct of such studies such as medication adherence, exercise, health outcomes that occur outside the medical home, and use of vitamin, supplement, and over-the-counter medications. In addition, these electronic data sources often do not reliably capture the patient perspective, which is critical for endpoints such as pain, quality of life, disease progression, and functional status. To fill these gaps, clinical trials or prospective studies that include patient-reported information are often needed. Mobile apps have the potential to increase efficiency in such prospective studies.

Existing mobile frameworks like Apple ResearchKit and ResearchStack provide a foundation on which to efficiently build and distribute mobile-based studies. A PubMed search on the key-
LAY SUMMARY
Research studies that use electronic medical records are unable to include information directly from patients. Electronic medical record data are created when a patient visits a clinician, meaning that health-related information that occurs outside a medical visit is not included. This type of information can include the use of vitamins, supplements, and over-the-counter medications, exercise, use of alcohol, use of other nonprescription drugs, and health events such as a rash or migraine that does not require a trip to the doctor. We developed a mobile app, the FDA MyStudies app, to collect this type of information directly from patients. The app allows patients to report information not available in the medical record and have that information combined with data from the medical record (e.g., cholesterol levels, blood pressure) to provide a better picture of the patient. To test the app, we invited pregnant women to volunteer to download the app and report information through questionnaires in the app. We then combined the patient-reported information with data from their medical records to provide a more complete picture of the patient for research. This approach can be used to help incorporate the patient voice in any type of research project using medical record data.

words ResearchKit and ResearchStack identified 10 studies conducted using an app built on the Apple ResearchKit framework.1–11

Still, challenges remain using existing mobile frameworks, especially for studies intended for regulatory purposes, in areas such as (1) consent, privacy, and security; (2) compliant enrollment and sustained engagement; and (3) extensibility and support of multiple therapeutic areas within a single mobile app framework.12,13 To address these challenges, the Food and Drug Administration (FDA) engaged Harvard Pilgrim Health Care Institute (HPHCI) through the FDA Sentinel Initiative Catalyst program to coordinate the development and pilot testing of the FDA MyStudies platform.14,15

The primary goal of the project was to build an open-source reusable platform comprised of a mobile device application and patient data storage environment that addresses the challenges noted above in a manner consistent with FDA’s regulatory needs regarding data security and traceability. Creating a platform that meets regulatory data security and privacy standards while remaining extensible to different types of studies and patient cohorts was central to the requirements and design of the platform.

As a proof-of-concept, we conducted a descriptive pilot study of exposures and health outcomes among pregnant women from the Kaiser Permanente Washington (KPWA) health system. Full pilot study objectives, methods, and results are reported elsewhere in a brief communication pending publication. The FDA MyStudies platform is generalizable and can be used and rebranded for studies in other therapeutic areas and patient populations and has recently been modified to enable contactless patient informed consent during the COVID pandemic.16

In this article, we describe the capabilities of the platform, how it expands the usability of existing mobile frameworks, and how it can help form a wholistic view of study participants. Open-source code and technical documentation are available to the public on GitHub.

MATERIALS AND METHODS

Requirements gathering
A workgroup consisting of members from FDA, Boston Technology Corporation (BTC), LabKey, Kaiser Permanente Washington Health Research Institute (KPWHRI), Vaccines and Medications in Pregnancy Surveillance System (VAMPSS), and HPHCI developed the mobile app platform business requirements. The workgroup also incorporated feedback from other FDA stakeholders to ensure the technical and hosting architecture was consistent with emerging FDA standards for mobile applications. During development, the KPWHRI team led focus groups that included seven women who were pregnant or had been pregnant within the past three years to provide feedback on a prototype system.

Design
The FDA MyStudies platform contains three elements: (1) an iOS and Android version of the mobile app, (2) a web-based configuration portal (WCP) for configuring studies and other elements accessed via the apps, and (3) a secure storage environment to manage study participant responses and consent forms. Applications developed under the FDA Sentinel Initiative must adhere to these security regulations, but the platform code can be implemented in environments with less stringent security requirements. Multiple apps, rather than a responsive design, were required to enable custom enhancements to the ResearchStack frameworks. Figure 1 illustrates how all system elements interact.

The storage environment consists of three independent servers: a response server to store data captured via the mobile app, a registration server to store participant information (email addresses and consent forms), and a metadata server for information configured in the WCP. This design was chosen to enable partitioning of patient identifiable information from response data. A unique set of credentials is required to access each server; there is no method to match email addresses and consent forms to response data without access to both relevant servers.

The response and registration servers are custom implementations of the LabKey Server product.17 Two add-ons were built for this project: (1) a module that automatically creates a new database schema for every new questionnaire, eliminating the need to manually create a schema for each new study; (2) the ability to produce a unique token, or enrollment token, which can be given to participants to restrict enrollment to a specified cohort or match data to external data sets. All three servers enforce role-based governance.

The platform stores data in a centralized location and does not interact directly with an EHR system as that represented a policy change outside the scope of this project.

Study materials, including questionnaire content, consent forms, eligibility questions, and app notifications, are configurable and distributed to the apps in real time via the WCP. All Apple ResearchKit and ResearchStack question types can be used in a questionnaire.
Participants respond to questionnaires at their convenience and responses are stored locally until submission or questionnaire expiration.

The mobile app and WCP were released to production in September 2017 and made publicly available via GitHub in November 2018.

RESULTS

Enrollment

The app was published in the Apple App Store and Google Play Store immediately before pilot study invitations were mailed to 1071 pregnant women who met minimum inclusion criteria. 81 Apple iOS users and 38 Android users downloaded the FDA MyStudies app and a total of 64 (6%) patients consented via the mobile app to participate in the study. Figure 2 shows the percent of those users that installed the app each week. 39% enrolled in week 1, 14% in week 2, 9% in week 3, and 14% in week 4. The slight increase in enrollment in week 4 is likely due to the second set of invitation letters sent out at that time.

Engagement

The pilot study collected data for 13 weeks. Half of the cohort (51%) engaged with the app for more than 4 weeks and the median period of engagement was 35 days. Table 1 shows the completion percentage for each survey distributed during the pilot study.

DISCUSSION

Extensibility and usability

The MyStudies platform is an extensible publicly available mobile data collection tool designed to support research studies intended for regulatory use. Other mobile apps designed for research are typically purpose built for one study and require programming expertise to reconfigure for new use cases; the MyStudies platform is designed to enable rapid redeployment for different studies leveraging the same underlying platform.

By adding a front-end application (ie the WCP) and secure storage environment to existing mobile frameworks, the platform allows simple user interface-based configuration, mobile patient consent, and secure data storage in a single platform.

In the pilot study, KPWHRI was able to link each woman’s unique enrollment token with her patient record in the KPWA EHR using a crosswalk file stored externally to the EHR. This linkage allowed patient-reported data from the app to be compared with data recorded in the EHR and to augment the EHR data to better support research studies; due to health system data governance requirements data from the app were not directly incorporated into the EHR but rather linked to EHR-derived research data set stored outside the EHR. Patient-reported information such as over-the-
counter medication use, use of alcohol, and illicit drugs can fill common gaps in the EHR, thereby better enabling EHR-based research to support study aims. The platform now allows the pushing of data directly to external systems such as EHRs.

Consent, privacy, and security
Mobile app uptake for research is a function of the effectiveness of the initial recruitment method used, possession of a smartphone capable of operating the app, and a willingness to download the app, authenticate, provide electronic consent, and use the app. The system conforms to stringent federal data privacy and security standards. The LabKey storage environment ensures data backup services, encryption, and log monitoring of the are enabled.\textsuperscript{17} The secure enrollment token process ensures indefinable information is not stored in the same server as patients’ responses.

Third-party review of the system for 21 CFR Part 11 compliance was beyond the scope of the project, but we are confident that the data storage environment is secure and supports auditing necessary for compliance with 21 CFR Part 11;\textsuperscript{18} the system was designed and built with that goal in mind via input from FDA stakeholders. Two-factor authentication (via email) is used during registration and app users can be authenticated by investigators if needed by matching email address to responses. Electronic signatures are required during each study consent process and the enrollment token ensures only the selected cohort can join. Signed consent forms are saved as PDFs.

### Table 1 Questionnaire completion by name

| Questionnaire name                                      | Women who completed at least 1 distribution of the questionnaire | % | Number of times completed* |
|--------------------------------------------------------|-----------------------------------------------------------------|---|---------------------------|
| Current weight\textsuperscript{b}                      | 59                                                              | 92 | 264                       |
| Initial study questionnaire                            | 59                                                              | 92 | 59                        |
| Medical condition history                              | 58                                                              | 91 | 58                        |
| Pregnancy status\textsuperscript{b}                    | 58                                                              | 91 | 288                       |
| Short-term illness history during pregnancy            | 53                                                              | 83 | 54                        |
| Pregnancy history                                      | 50                                                              | 78 | 50                        |
| Information about you                                  | 48                                                              | 75 | 48                        |
| Smoking and vaping history                             | 45                                                              | 70 | 45                        |
| Vaccine history during pregnancy                       | 44                                                              | 69 | 44                        |
| Vitamin use history                                    | 40                                                              | 63 | 40                        |
| Current medical condition information                  | 39                                                              | 61 | 106                       |
| History of alcohol exposure                            | 39                                                              | 61 | 39                        |
| History of marijuana or cannabis exposure              | 39                                                              | 61 | 39                        |
| History of recreational drug exposure                  | 39                                                              | 61 | 39                        |
| Recent short-term illness\textsuperscript{b}           | 36                                                              | 56 | 92                        |
| Current smoking and vaping exposure\textsuperscript{b} | 31                                                              | 48 | 45                        |
| Current vitamin use\textsuperscript{b}                | 30                                                              | 47 | 44                        |
| Current alcohol exposure\textsuperscript{b}            | 26                                                              | 41 | 26                        |
| Current marijuana or cannabis exposure\textsuperscript{b} | 26                                                          | 41 | 26                        |
| Current recreational drug exposure\textsuperscript{b}  | 26                                                              | 41 | 26                        |
| Vaccine exposure update\textsuperscript{b}             | 13                                                              | 20 | 14                        |
| Current pregnancy outcomes\textsuperscript{b}         | 7                                                               | 11 | 7                         |

*Three women did not answer any questionnaires.
\textsuperscript{b}Recurring questionnaire.

\textsuperscript{17} The secure enrollment token process ensures indefinable information is not stored in the same server as patients’ responses.

\textsuperscript{18} The system was designed and built with that goal in mind via input from FDA stakeholders.
in the storage environment and accessible to investigators with appropriate permissions.

Limitations
Use of the app requires individuals to have an Android or iOS-compatible mobile device, which may influence the composition of the study population. However, smartphone and tablet usage is widespread and growing, and it is possible to combine the app-based study approach with alternative approaches such as a web-based survey instrument. We note that some patient populations, for example, those who are unable to engage with a mobile app due to their disease state or who are uncomfortable with the technology, may not be good candidates for this data collection and engagement approach.

The study had a fixed start date and survey schedule, so some questionnaires expired before all patients were enrolled. This potentially influenced engagement as not all participants had the opportunity to complete all questionnaires. The newest version of the app now available on GitHub allows for staggered enrollment which addresses this limitation.

Lastly, the system is designed to be downloaded from GitHub and used independently of the existing FDA infrastructure built for the pilot. Therefore, some engagement with software developers may be required to locally install the system and rebrand the app code with specific branding desired by an organization and study. An Apple and/or Google app developer account is also required to distribute the app. The compliance version of the LabKey server is required to ensure all security features described but a free version of the LabKey server is available. Implementation of new studies using the app should plan several months of preparation for each new study, depending on the study design and complexity of the questions. Still, all elements of the system are designed to work seamlessly together to provide an intuitive and compliant mobile data collection platform that supports multiple therapeutic areas in a single app. The HPHCI workgroup members and the technical partners are using the MyStudies app to support multiple clinical studies in different disease areas and have recently released a version to support Covid-19 clinical trials. In addition, Google is now working on a 1-click implementation for the app.

CONCLUSION
The pilot study demonstrated that the FDA MyStudies platform can be used to collect data directly from patients while meeting the current challenges presented by mobile apps with regards to (1) consent, privacy, and security; (2) enrollment and engagement; and (3) extensibility and represents a substantial expansion to the usability of existing mobile frameworks.

Given the scope of information provided, the app appears capable of expanding the depth and diversity of patient-reported information available to support clinical research, either alone or in combination with other electronic data sources such as EHRs, claims data, and registries. Continued app development using the information in the public domain will likely increase usability, enable the integration of other real-world data sources, and enhance the overall ease with which the patient perspective can be included in clinical research. This work fills helps to address a critical gap by enabling investigators and policy makers to incorporate the patient voice in critical public health research.

AUTHORS’ CONTRIBUTIONS
Each author made substantial contributions to the study design, study implementation, and analysis, and each contributed to drafting, reviewing, and approving the final manuscript.

ACKNOWLEDGMENTS
The authors are grateful to the members of the Kaiser Permanente Washington team who participated in survey development, testing, and data analysis including Ladia Albertson-Junks and Linda Keil. Patient representatives Kacie Washington and Karen Byeman provided substantial input regarding the design of the system and study questionnaires. Testing for the application could also have not been completed without the support of additional staff members from Kaiser Permanente Washington and Harvard Pilgrim Health Care Institute along with Susan Hert of the LabKey team. We would also like to acknowledge Karen Staman for her editorial support.

FUNDING
This work was supported by the Patient-Centered Outcomes Research Trust Fund through a competitive application process administered by the Assistant Secretary for Planning and Evaluation (ASPE) of the Department of Health and Human Services (contract number HHSF223201400030I) and Interagency Agreement (#750115F060034).

Conflict of interest statement. Several authors (SD, SR, AR) are employees of companies that provide support to the MyStudies mobile app. The other authors have no conflicts to report.

REFERENCES
1. Yoshimura Y, Ishijima M, Ishibashi M, et al. A nationwide observational study of locomotive syndrome in Japan using the ResearchKit: the Locomotor Study. J Orthop Sci 2019; 24 (6): 1094–104.
2. Radin JM, Steinhubl SR, Su AI, et al. The Healthy Pregnancy Research Program: transforming pregnancy research through a ResearchKit app. NPJ Digit Med 2018; 1: 45.
3. Egger HL, Dawson G, Hashemi J, et al. Automatic emotion and attention analysis of young children at home: a ResearchKit autism feasibility study. NPJ Digit Med 2018; 1: 20.
4. Yamauchi S, Waki K, Nanmya Y, Nangaku M, Kadowaki T, Ohe K. Usability patterns of GlucoseNote, a self-management smartphone app, based on ResearchKit for patients with type 2 diabetes and prediabetes. JMIR Mhealth Uhealth 2019; 7 (4): e13204.
5. Crouthamel M, Quattrociocchi E, Watts S, et al. Using a ResearchKit smartphone app to collect rheumatoid arthritis symptoms from real-world participants: feasibility study. JMIR Mhealth Uhealth 2018; 6 (9): e177.
6. Chan YY, Bot BM, Zweig M, et al. The asthma mobile health study, smartphone data collected using ResearchKit. Sci Data 2018; 5 (1): 180096.
7. Chan YY, Wang P, Rogers L, et al. The Asthma Mobile Health Study, a large-scale clinical observational study using ResearchKit. Nat Biotechnol 2017; 35 (4): 354–62.
8. Zerns M, Wosas P, Suedkamp NP, Niemeyer P. “Back on track”: a mobile app observational study using Apple’s ResearchKit framework. JMIR Mhealth Uhealth 2017; 5 (2): e23.
9. Webster DE, Suver C, Docter M, et al. The Mole Mapper Study, mobile phone skin imaging and melanoma risk data collected using ResearchKit. Sci Data 2017; 4 (1): 170005.
10. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using. Sci Data 2016; 3 (1): 160011.
11. Hershman SG, Bot BM, Shcherbina A, et al. Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. Sci Data 2019; 6 (1): 24.
12. Moore S, Tassé A-M, Thorogood A, Winship I, Zawati M, Doerr M. Consent processes for mobile app mediated research: systematic review. JMIR mHealth Uhealth 2017; 5 (8): e126.
13. Schmitz H, Howe CL, Armstrong DG, Subbian V. Leveraging mobile health applications for biomedical research and citizen science: a scoping review. J Am Med Informatics Assoc 2018; 25 (12): 1685–95.
14. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl 1): 23–31.
15. Platt R, Brown JS, Robb M, et al. The FDA sentinel initiative—an evolving national resource. N Engl J Med 2018; 379 (22): 2091–3.
16. Policy for Device Software Functions and Mobile Medical Applications. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications. Accessed June 2, 2020.
17. LabKey Server - Research’s Most Flexible Software Platform for Insight. LabKey. https://www.labkey.com/products-services/labkey-server/. Accessed June 26, 2019.
18. FDA’s MyStudies Application (App) Technical Background. https://www.fda.gov/drugs/science-and-research-drugs/fdas-mystudies-application-app-technical-background. Accessed October 20, 2020.
19. Mobile Fact Sheet. 2019.http://www.pewinternet.org/fact-sheet/mobile/. Accessed August 1, 2019.
20. COVID MyStudies Application (App) https://www.fda.gov/drugs/science-and-research-drugs/covid-mystudies-application-app. Accessed October 20, 2020.
21. FDA My Studies comes to Google cloud. https://cloud.google.com/blog/topics/healthcare-life-sciences/fda-mystudies-comes-to-google-cloud. Accessed October 20, 2020.